ETFs positioned on Grifols, S.A.

Name Weight AuM 1st Jan change Investor Rating
0.98% 113 M€ +16.86% -
0.21% 2 M€ -.--%
0.21% 1,005 M€ +9.15%
0.16% 20 M€ +16.14% -
0.05% 6 M€ -.--% -
0.03% 6 M€ -.--%
0.02% 10 M€ -3.35% -
0.02% 0 M€ -.--% -
0.02% 23 M€ -.--% -
0.02% 786 M€ -.--%
0.01% 329 M€ +29.62%
0.01% 33,076 M€ +15.37% -
0.01% 607 M€ -0.19%
0.01% 1,166 M€ +0.26% -
0.01% 54 M€ 0.00% -
0.01% 206 M€ -.--%
0.01% 24 M€ +10.04% -
0.01% 284 M€ -.--%
0.01% 503 M€ +22.48% -
0.00% 9 M€ +5.19% -
0.00% 122 M€ +12.43% -
0.00% 7 M€ +0.11% -
Logo Grifols, S.A.
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Employees
23,000
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
surperformance-ratings-light-chart GRIFOLS-S-AMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
8.894EUR
Average target price
16.68EUR
Spread / Average Target
+87.55%
Consensus

Quarterly revenue - Rate of surprise